Denosumab for Prevention of Fractures in Postmenopausal Women With Osteoporosis
Steven R. Cummings(University of California, San Francisco), Claus Christiansen(Center for Clinical & Basic Research), Suresh Siddhanti(Amgen (United States)), Michael R. McClung(Bone Health and Osteoporosis Foundation), Holly Brenza Zoog(Amgen (United States)), Ian R. Reid(University of Auckland), Andrea Wang(Amgen (United States)), Richard Eastell(University of Sheffield), Štěpán Kutílek, Ethel S. Siris(Columbia University Irving Medical Center), Javier San Martín(Universidad Nacional de Educación a Distancia), Silvano Adami(University of Verona), Matt Austin(Amgen (United States)), Cesar Libanati(Amgen (United States)), Pierre Delmas(Université Claude Bernard Lyon 1), José Zanchetta(Universidad del Salvador)
Cited by 61
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Body mass index as a predictor of fracture risk: A meta-analysis
|Osteoporosis International|2005|1.6k
Predictive Value of BMD for Hip and Other Fractures
|Journal of Bone and Mineral Research|2005|1.5k
The clinician’s guide to prevention and treatment of osteoporosis
|Osteoporosis International|2022|1.3k